NATCO Pharma Ltd.
Industry Group: Pharmaceuticals
Country/Region: India
Identifier: BOM:524816
Natco Pharma Ltd is a drug manufacturing company. Natco aims to make specialty medicines accessible to all by manufacturing niche pharmaceutical products backed by its research and development capabilities. While the vast majority of the company's revenue is generated in India, the company looks internationally for growth opportunities. The company maintains a presence in Oncology and Hepatology treatment areas. Natco's active pharmaceutical ingredient segment APIs forms a core part of the company's business. The company operates in two different business segments: pharmaceuticals and agrochemicals. It derives maximum revenue from Pharmaceuticals Segment.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 616 out of 850
Universe
Global Universe 12049 out of 15080
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Joincare Pharmaceutical Group Industry Co., Ltd. |
31.2
High
|
540 out of 850 |
| China Resources Double-Crane Pharmaceutical Co., Ltd. |
32.4
High
|
575 out of 850 |
| NATCO Pharma Ltd. |
33.1
High
|
616 out of 850 |
| Jilin Aodong Pharmaceutical Group Co., Ltd. |
33.2
High
|
620 out of 850 |
| Tianjin Pharmaceutical Da Ren Tang Group Corp. Ltd. |
34.4
High
|
674 out of 850 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted NATCO Pharma Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level
Contributing Events
Highest Controversy Events Locations
